Cargando…
Lonafarnib and everolimus reduce pathology in iPSC-derived tissue engineered blood vessel model of Hutchinson-Gilford Progeria Syndrome
Hutchinson-Gilford Progeria Syndrome (HGPS) is a rare, fatal genetic disease that accelerates atherosclerosis. With a limited pool of HGPS patients, clinical trials face unique challenges and require reliable preclinical testing. We previously reported a 3D tissue engineered blood vessel (TEBV) micr...
Autores principales: | Abutaleb, Nadia O., Atchison, Leigh, Choi, Leandro, Bedapudi, Akhil, Shores, Kevin, Gete, Yantenew, Cao, Kan, Truskey, George A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10050176/ https://www.ncbi.nlm.nih.gov/pubmed/36977745 http://dx.doi.org/10.1038/s41598-023-32035-3 |
Ejemplares similares
-
iPSC-Derived Endothelial Cells Affect Vascular Function in a Tissue-Engineered Blood Vessel Model of Hutchinson-Gilford Progeria Syndrome
por: Atchison, Leigh, et al.
Publicado: (2020) -
Impaired LEF1 Activation Accelerates iPSC-Derived Keratinocytes Differentiation in Hutchinson-Gilford Progeria Syndrome
por: Mao, Xiaojing, et al.
Publicado: (2022) -
A Tissue Engineered Blood Vessel Model of Hutchinson-Gilford Progeria Syndrome Using Human iPSC-derived Smooth Muscle Cells
por: Atchison, Leigh, et al.
Publicado: (2017) -
Mechanisms of angiogenic incompetence in Hutchinson–Gilford progeria via downregulation of endothelial NOS
por: Gete, Yantenew G., et al.
Publicado: (2021) -
Lonafarnib improves cardiovascular function and survival in a mouse model of Hutchinson-Gilford progeria syndrome
por: Murtada, Sae-Il, et al.
Publicado: (2023)